ECSP088517A - Procedimiento para la preparacion del inhibidor del ciclo celular-779 cristalino y purificado - Google Patents

Procedimiento para la preparacion del inhibidor del ciclo celular-779 cristalino y purificado

Info

Publication number
ECSP088517A
ECSP088517A EC2008008517A ECSP088517A ECSP088517A EC SP088517 A ECSP088517 A EC SP088517A EC 2008008517 A EC2008008517 A EC 2008008517A EC SP088517 A ECSP088517 A EC SP088517A EC SP088517 A ECSP088517 A EC SP088517A
Authority
EC
Ecuador
Prior art keywords
crystal
procedure
preparation
cycle inhibitor
purified cellular
Prior art date
Application number
EC2008008517A
Other languages
English (en)
Inventor
Wei Tong
Subodh S Deshmukh
Adam P Michaud
Chunhao Zhang
Clifford William Coughlin
Lynn M Phelan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088517A publication Critical patent/ECSP088517A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona CCI-779 cristalino purificado y procedimientos para preparar el mismo.
EC2008008517A 2005-12-07 2008-06-09 Procedimiento para la preparacion del inhibidor del ciclo celular-779 cristalino y purificado ECSP088517A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74800605P 2005-12-07 2005-12-07

Publications (1)

Publication Number Publication Date
ECSP088517A true ECSP088517A (es) 2008-07-30

Family

ID=37891446

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008517A ECSP088517A (es) 2005-12-07 2008-06-09 Procedimiento para la preparacion del inhibidor del ciclo celular-779 cristalino y purificado

Country Status (18)

Country Link
US (1) US7553843B2 (es)
EP (1) EP1957500A1 (es)
JP (1) JP2009518413A (es)
KR (1) KR20080077618A (es)
CN (1) CN101321769A (es)
AR (1) AR058282A1 (es)
AU (1) AU2006322029A1 (es)
BR (1) BRPI0619493A2 (es)
CA (1) CA2630784A1 (es)
CR (1) CR9988A (es)
EC (1) ECSP088517A (es)
GT (1) GT200800089A (es)
IL (1) IL191546A0 (es)
NO (1) NO20082379L (es)
PE (1) PE20071041A1 (es)
RU (1) RU2008121240A (es)
TW (1) TW200732342A (es)
WO (1) WO2007067565A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754207B2 (en) 2009-09-25 2014-06-17 Cadila Healthcare Limited Process for the preparation of rapamycin derivatives
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358909A (en) * 1991-02-27 1994-10-25 Nippon Steel Corporation Method of manufacturing field-emitter
US5358908A (en) * 1992-02-14 1994-10-25 Micron Technology, Inc. Method of creating sharp points and other features on the surface of a semiconductor substrate
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
DE60136200D1 (de) 2000-09-19 2008-11-27 Wyeth Corp Wasserlösliche rapamycin-ester
FR2826961B1 (fr) * 2001-07-06 2005-09-30 Atofina Procede de preparation d'anhydride (meth) acrylique
WO2005010010A1 (en) * 2003-07-16 2005-02-03 Wyeth Cci-779 isomer c
KR20060057605A (ko) * 2003-08-07 2006-05-26 와이어쓰 Ｃｃｉ-779의 위치선택적 합성 방법
JP2007504226A (ja) * 2003-09-03 2007-03-01 ワイス 非晶質状のラパマイシンの３−ヒドロキシ−２−（ヒドロキシメチル）−２−メチルプロピオン酸との４２−エステル、およびそれを含むその医薬組成物
SG152234A1 (en) * 2004-04-14 2009-05-29 Wyeth Corp Regiospecific synthesis of rapamycin 42-ester derivatives
ATE410431T1 (de) * 2004-04-14 2008-10-15 Wyeth Corp Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper
AU2005292647A1 (en) * 2004-08-10 2006-04-13 Wyeth CCI-779 derivatives and methods of making same
US7273874B2 (en) * 2004-12-20 2007-09-25 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
DK1828202T3 (da) * 2004-12-20 2012-05-07 Wyeth Llc Rapamycinanaloge samt deres anvendelse ved behandling af neurologiske, proliferative og inflammatoriske lidelser
KR20070107030A (ko) * 2005-02-09 2007-11-06 와이어쓰 Ｃｃｉ-７７９ 다형체 및 그의 용도
AU2006218916A1 (en) * 2005-03-02 2006-09-08 Wyeth Recovery of CCI-779 from mother liquors
US7241771B2 (en) * 2005-03-07 2007-07-10 Wyeth Oxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin

Also Published As

Publication number Publication date
TW200732342A (en) 2007-09-01
RU2008121240A (ru) 2010-01-20
AR058282A1 (es) 2008-01-30
BRPI0619493A2 (pt) 2016-09-06
CN101321769A (zh) 2008-12-10
KR20080077618A (ko) 2008-08-25
IL191546A0 (en) 2008-12-29
WO2007067565A1 (en) 2007-06-14
US20070129395A1 (en) 2007-06-07
PE20071041A1 (es) 2007-12-07
AU2006322029A1 (en) 2007-06-14
JP2009518413A (ja) 2009-05-07
CR9988A (es) 2008-07-29
NO20082379L (no) 2008-09-04
US7553843B2 (en) 2009-06-30
GT200800089A (es) 2008-12-04
CA2630784A1 (en) 2007-06-14
EP1957500A1 (en) 2008-08-20

Similar Documents

Publication Publication Date Title
GT200600264A (es) Modificaciones cristalinas de piraclostrobina
ECSP078055A (es) Formas sólidas cristalinas de tigeciclina y métodos para preparar las mismas
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
CO6640285A2 (es) 5-alquinil-pirimidinas
TW200716512A (en) Processes for preparing cinacalcet hydrochloride crystal form I
ECSP077268A (es) Polimorfo ii de rapamicina y los usos de los mismos
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
ATE528989T1 (de) Kristalline feste rasagilin-base
CR20180142A (es) ANTICUERPOS ANTI-FAP Y MÉTODOS DE USO(Divisional Exp: 2013-0038)
CR11861A (es) Compuestos organicos
HN2006011218A (es) Composiciones de tigeciclina y métodos de preparación
CR11818A (es) Derivados de triazol utiles para el tratamiento de enfermedades
ECSP088905A (es) Nuevos compuestos
AR061311A1 (es) Procesos para preparar clorhidrato de cinacalcet y formas polimorficas del mismo
CL2009001686A1 (es) Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados.
ECSP11010786A (es) 5-alquinil-pirimidinas
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina
UY29434A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como inhibidores de la inflamacinn
SV2005002015A (es) Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo - ref. wyth0008-504 (am101302)
UY31700A (es) Tiazolil-dihidro-indazoles
CR9257A (es) Polimorfo cci-779 y uso del mismo
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida
ECSP11011454A (es) 5-alquinil-piridinas
NI200700175A (es) Procesos para la preparación de alcoholes de aminoetoxibencilo
ECSP088517A (es) Procedimiento para la preparacion del inhibidor del ciclo celular-779 cristalino y purificado